Efficacy and safety of first-line immunotherapy and targeted therapy in advanced HCC: a network meta-analysis with subgroup analysis based on HBV and HCV infection | Synapse
March 3, 2026Open Access
Efficacy and safety of first-line immunotherapy and targeted therapy in advanced HCC: a network meta-analysis with subgroup analysis based on HBV and HCV infection
Key Points
Immunotherapy and targeted therapy can significantly improve outcomes in advanced HCC.
Survival rates differ based on whether patients are infected with HBV or HCV.
Network meta-analysis utilized data from multiple trials to compare therapeutic efficacy.
Results may inform treatment decisions, but further studies are needed for validation.